IMVT▼
Immunovant Q1 2027 Earnings Call Transcript
Immunovant reported a cash balance of $797.8 million as of June 30, 2026, which management stated provides a runway to the potential commercial launch of IMVT-1402 in Graves' disease. Research and development expenses were $142.6 million for the quarter, compared to $101.2 million in the prior year, primarily due to increased clinical trial activities for IMVT-1402 and contract manufacturing costs. The company reported a net loss of $153.2 million, or $0.75 per common share, for the three months ended June 30, 2026, and a non-GAAP net loss of $139.4 million excluding $13.8 million in non-cash stock-based compensation. Management expects topline data from the proof-of-concept trial in cutaneous lupus erythematosus in the second half of 2026, and topline data for the potentially registrational trials in Graves' disease and myasthenia gravis in calendar year 2027. Roivant, the parent company, received an upfront payment of $950 million from the Moderna settlement, with $770 million allocated to Genevant and the remainder to Arbutus, and reported a cash balance of just under $4 billion prior to the receipt of the Moderna settlement funds.
The Motley Fool·13dRead more ▾
IMVT
Immunovant to report first quarter 2026 results and business update on August 6
Immunovant announced it will report financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Majority stockholder Roivant Sciences will host a conference call and webcast at 8:00 a.m. Eastern Time that same day, which will include a business update for Immunovant. The archived webcast will be available on Immunovant's website after the call.
GlobeNewswire·34dRead more ▾
IMVT▼
Kuehn Law investigates Immunovant officers and directors for potential fiduciary breaches
Kuehn Law, PLLC is investigating whether certain officers and directors of Immunovant, Inc. breached their fiduciary duties to shareholders. The shareholder litigation law firm announced the investigation on July 20, 2026, focusing on potential self-dealing. Long-term Immunovant stockholders may be entitled to damages and corporate governance reforms. Shareholders are encouraged to contact Justin Kuehn, Esq. at justin@kuehn.law or by calling (833) 672-0814 for a free consultation with no obligation.
GlobeNewswire·37dRead more ▾
Biotech & Genomic Medicine▲
Cutaneous Lupus Erythematosus Market to Grow at 8% CAGR Through 2036, Reaching USD 650 Million in 2025
The cutaneous lupus erythematosus market across the seven major markets was valued at USD 650 million in 2025 and is projected to expand at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the market in 2025, representing around 60% of total diagnosed prevalent cases in the seven major markets, which also include the EU4 countries Germany, France, Italy, and Spain, the United Kingdom, and Japan. Antimalarials contributed over 50% of total annual revenue in 2025 across these markets. Growth is being driven by rising autoimmune disease prevalence, improved diagnosis, and a pipeline of emerging targeted therapies such as Litifilimab from Biogen, Daxdilimab from Amgen and Horizon Therapeutics, SOTYKTU from Bristol Myers Squibb, IMVT-1402 from Immunovant Sciences, VENT-03 from Ventus Therapeutics, CNTY-101 from Century Therapeutics, Anifrolumab from AstraZeneca, and Enpatoran from Merck. Biogen's Litifilimab received breakthrough therapy designation from the US FDA in January 2026 and reported positive Phase II results in March 2026, while Amgen announced positive Phase II results for Daxdilimab in discoid lupus erythematosus in 2026 and is considering advancing it to Phase III.
DelveInsight·65dRead more ▾
IMVT
Immunovant shares rise 3.6% since wider-than-expected quarterly loss
Immunovant shares have gained about 3.6% over the past month, outperforming the S&P 500, following a fourth-quarter 2026 net loss of 73 cents per share that was wider than the Zacks Consensus Estimate of a 60-cent loss. Research and development expenses climbed 51.9% to $142.3 million, driven by clinical activities for IMVT-1402 and $39 million in costs tied to the discontinuation of batoclimab. Cash and cash equivalents stood at approximately $902.1 million as of March 31, 2026, which the company expects will fund operations through the commercial launch of IMVT-1402 for GD. Analysts have been revising estimates downward, and the stock currently carries a Zacks Rank #3, or Hold, with an aggregate VGM Score of F.
Zacks Investment Research·68dRead more ▾
Biotech & Genomic Medicine▲
Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to Grow Through 2036 on Advancing Clinical Research
The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.
PR Newswire·69dRead more ▾